Psoriasis: Is ustekinumab superior to etanercept for psoriasis?

Nature Reviews Rheumatology

Volumn 6, Issue 9, 2010, Pages 500-501

  Kuhn, Annegret ^a   Luger, Thomas A ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 23; PLACEBO; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTHROPATHY; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG USE; FOLLOW UP; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LONG TERM CARE; MAINTENANCE THERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SHORT COURSE THERAPY; SHORT SURVEY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956297639     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2010.134     Document Type: Short Survey

References (10)

1. schön, M. P. & Boehncke, w. H. Psoriasis. N. Engl. J. Med. 352, 1899-1912 (2005).
2. Gottlieb, A. B. et al. TnF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J. Immunol. 175, 2721-2729 (2005).
3. Zaba, L. C. et al. Amelioration of epidermal hyperplasia by TnF inhibition is associated with reduced Th17 responses. J. Exp. Med. 204, 3183-3194 (2007).
4. McKenzie, B. s., Kastelein, R. A. & Cua, D. J. Understanding the iL-23-iL-17 immune pathway. Trends Immunol. 27, 17-23 (2006).
5. Leonardi, C. L. et al. efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOeniX 1). Lancet 371, 1665-1674 (2008).
6. Papp, K. A. et al. efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOeniX 2). Lancet 371, 1675-1684 (2008).
7. schmidt, C. Ustekinumab poised to enter the psoriasis market. Nat. Biotech. 26, 1317-1318 (2008).
8. Griffiths, C. e. et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 362, 118-128 (2010).
9. Trial watch: novel biologic for psoriasis shows superiority over current best-seller. Nat. Rev. Drug Discov. 7, 880-881 (2008).
10. Gottlieb, A. et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373, 633-640 (2009).